Publication de Nicole Delepine : Pharmacokinetic modelling of Ifosfamide during continuous infusion over 120 hours at the dose of 6 g/m².

Nicole delépine, le site officiel English Version Version Française
Accueil Site officiel ACCUEIL
Accueil du site officiel de Nicole Delepine
publication cancérologue réputé nicole delepine ostéosarcome
sarcome ewing publications du docteur nicole delepine
Publié sur : Anticancer Research vol. 19, n°1, 837-842. Meeting abstract. Abstract n° 873 - 1999
Voir la version PDF de cette publication : Document PDF | Publication sur le site du média : Document www
Pharmacokinetic modelling of Ifosfamide during continuous infusion over 120 hours at the dose of 6 g/m².
P. Passe, G. Delépine, S. Urien, J.C. Desbois, P. Arnaud. F. Traore, F. Brion, Nicole Delepine

Pharmacokinetic modelling of ifosfamide during continuous infusion over 120 hours at the dose of 6 g/m2 ().


Abstract:


Ifosfamide (IFX) pharmacokinetics (PK) (prodrug and metabolites) is promising to be one of the most important means to adapt doses and obtain better dose intensity in the future. Therefore, we tried to find the best modelling for IFX PK.

Methods:
We studied IFX PK in 12 patients aged 8-19 years receiving 16 courses of IFX continuously infused over 5 days at a dosage of 6 g/m2 per course. IFX serum concentrations were measured by gas chromatography with thermoionic detection. We applied two monocompartmental PK models to these data: Boddy's model (Cancer Chem Pharmacol; 36:53-60 1995) and Levy's model (J Pharmacol Biopharm; 7:6 1979) that we proposed. They both describe the auto-induction of IFX. PK parameters were estimated by non linear regression. Studied variables were volume of distribution (Vd.), clearance at the beginning of the induction (Cli), clearance extrapolated at infinite (Clf), clearance at 120 hours (C1120), a rate constant (Kc) that relates the clearance variations to time, and lag time that.







publications médicales


sarcome d'ewing
nicole delepine cancer tumeur ostéosarcome
Facebook Tweeter Google+